ArticleScientific reports2025

Clinical utility of comprehensive genomic profiling versus Oncomine Dx target test in pathological stage II-III non-small cell lung cancer.

Kaito Yano et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.